Cytochrome b561 Serves as a Potential Prognostic Biomarker and Target for Breast Cancer

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Duffy MJ, Walsh S, McDermott EW, Crown J. Biomarkers in breast cancer: where are we and where are we going? Adv Clin Chem. 2015;71:1–23.
   PubMed Web of Science ®Google Scholar
• Asard H, Barbaro R, Trost P, Berczi A. Cytochromes b561: ascorbate-mediated trans-membrane electron transport. Antioxid Redox Signal. 2013;19(9):1026–1035. doi:10.1089/ars.2012.5065
   PubMed Web of Science ®Google Scholar
• Lane DJ, Bae DH, Merlot AM, Sahni S, Richardson DR. Duodenal cytochrome b (DCYTB) in iron metabolism: an update on function and regulation. Nutrients. 2015;7(4):2274–2296. doi:10.3390/nu7042274
   PubMed Web of Science ®Google Scholar
• Torti SV, Manz DH, Paul BT, Blanchette-Farra N, Torti FM. Iron and cancer. Annu Rev Nutr. 2018;38:97–125. doi:10.1146/annurev-nutr-082117-051732
   PubMed Web of Science ®Google Scholar
• Shibao CA, Garland EM, Black BK, et al. Congenital absence of norepinephrine due to CYB561 mutations. Neurology. 2020;94(2):e200–e204. doi:10.1212/WNL.0000000000008734
   PubMed Web of Science ®Google Scholar
• Srivastava M. Genomic structure and expression of the human gene encoding cytochrome b561, an integral protein of the chromaffin granule membrane. J Biol Chem. 1995;270(39):22714–22720. doi:10.1074/jbc.270.39.22714
   PubMed Web of Science ®Google Scholar
• Srivastava A, Mousses S, Dobi A, Leighton X. Elevated expression of the cytochrome b561, a neuroendocrine vesicle protein, in castration resistant prostate tumors. Cancer Biomark. 2010;7(1):17–23. doi:10.3233/CBM-2010-0142
   PubMed Web of Science ®Google Scholar
• Goldman MJ, Craft B, Hastie M, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38(6):675–678. doi:10.1038/s41587-020-0546-8
   PubMed Web of Science ®Google Scholar
• Cheng PF, Dummer R, Levesque MP. Data mining The Cancer Genome Atlas in the era of precision cancer medicine. Swiss Med Wkly. 2015;145:w14183. doi:10.4414/smw.2015.14183
   PubMed Web of Science ®Google Scholar
• Chang JW, Kuo WH, Lin CM, et al. Wild-type p53 upregulates an early onset breast cancer-associated gene GAS7 to suppress metastasis via GAS7-CYFIP1-mediated signaling pathway. Oncogene. 2018;37(30):4137–4150. doi:10.1038/s41388-018-0253-9
   PubMed Web of Science ®Google Scholar
• Hall P, Ploner A, Bjohle J, et al. Hormone-replacement therapy influences gene expression profiles and is associated with breast-cancer prognosis: a cohort study. BMC Med. 2006;4:16. doi:10.1186/1741-7015-4-16
   PubMed Web of Science ®Google Scholar
• Pawitan Y, Bjohle J, Amler L, et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res. 2005;7(6):R953–R964. doi:10.1186/bcr1325
   PubMed Web of Science ®Google Scholar
• Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391):603–607. doi:10.1038/nature11003
   PubMed Web of Science ®Google Scholar
• Uhlen M, Fagerberg L, Hallstrom BM, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419. doi:10.1126/science.1260419
   PubMed Web of Science ®Google Scholar
• Thul PJ, Akesson L, Wiking M, et al. A subcellular map of the human proteome. Science. 2017;356(6340). doi:10.1126/science.aal3321
   PubMed Web of Science ®Google Scholar
• Uhlen M, Zhang C, Lee S, et al. A pathology atlas of the human cancer transcriptome. Science. 2017;357(6352). doi:10.1126/science.aan2507
   PubMed Web of Science ®Google Scholar
• Mizuno H, Kitada K, Nakai K, Sarai A. PrognoScan: a new database for meta-analysis of the prognostic value of genes. BMC Med Genomics. 2009;2:18. doi:10.1186/1755-8794-2-18
   PubMed Web of Science ®Google Scholar
• Gyorffy B, Lanczky A, Eklund AC, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1809 patients. Breast Cancer Res Treat. 2010;123(3):725–731. doi:10.1007/s10549-009-0674-9
   PubMed Web of Science ®Google Scholar
• Vasaikar SV, Straub P, Wang J, Zhang B. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2018;46(D1):D956–D963. doi:10.1093/nar/gkx1090
   PubMed Web of Science ®Google Scholar
• Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556–W560. doi:10.1093/nar/gkz430
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1523. doi:10.1038/s41467-019-09234-6
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607–D613. doi:10.1093/nar/gky1131
   PubMed Web of Science ®Google Scholar
• Stark C, Breitkreutz BJ, Reguly T, Boucher L, Breitkreutz A, Tyers M. BioGRID: a general repository for interaction datasets. Nucleic Acids Res. 2006;34:D535–D539. doi:10.1093/nar/gkj109
   PubMed Web of Science ®Google Scholar
• Turei D, Korcsmaros T, Saez-Rodriguez J. OmniPath: guidelines and gateway for literature-curated signaling pathway resources. Nat Methods. 2016;13(12):966–967. doi:10.1038/nmeth.4077
   PubMed Web of Science ®Google Scholar
• Li T, Wernersson R, Hansen RB, et al. A scored human protein-protein interaction network to catalyze genomic interpretation. Nat Methods. 2017;14(1):61–64. doi:10.1038/nmeth.4083
   PubMed Web of Science ®Google Scholar
• Bader GD, Hogue CW. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinform. 2003;4:2. doi:10.1186/1471-2105-4-2
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–e110. doi:10.1158/0008-5472.CAN-17-0307
   PubMed Web of Science ®Google Scholar
• Li B, Severson E, Pignon JC, et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 2016;17(1):174. doi:10.1186/s13059-016-1028-7
   PubMed Web of Science ®Google Scholar
• Ru B, Wong CN, Tong Y, et al. TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics. 2019;35(20):4200–4202. doi:10.1093/bioinformatics/btz210
   PubMed Web of Science ®Google Scholar
• Chen X, Xu C, Hong S, et al. Immune cell types and secreted factors contributing to inflammation-to-cancer transition and immune therapy response. Cell Rep. 2019;26(7):1965–1977 e1964. doi:10.1016/j.celrep.2019.01.080
   PubMed Web of Science ®Google Scholar
• Manning M, Jiang Y, Wang R, et al. Pan-cancer analysis of RNA methyltransferases identifies FTSJ3 as a potential regulator of breast cancer progression. RNA Biol. 2020;17(4):474–486. doi:10.1080/15476286.2019.1708549
   PubMed Web of Science ®Google Scholar
• Saito Y, Li L, Coyaud E, et al. LLGL2 rescues nutrient stress by promoting leucine uptake in ER(+) breast cancer. Nature. 2019;569(7755):275–279. doi:10.1038/s41586-019-1126-2
   PubMed Web of Science ®Google Scholar
• Terp MG, Lund RR, Jensen ON, Leth-Larsen R, Ditzel HJ. Identification of markers associated with highly aggressive metastatic phenotypes using quantitative comparative proteomics. Cancer Genomics Proteomics. 2012;9(5):265–273.
   PubMed Web of Science ®Google Scholar
• Du X, Shen X, Dai L, Bi F, Zhang H, Lu C. PSMD12 promotes breast cancer growth via inhibiting the expression of pro-apoptotic genes. Biochem Biophys Res Commun. 2020;526(2):368–374. doi:10.1016/j.bbrc.2020.03.095
   PubMed Web of Science ®Google Scholar
• Katz E, Dubois-Marshall S, Sims AH, et al. A gene on the HER2 amplicon, C35, is an oncogene in breast cancer whose actions are prevented by inhibition of Syk. Br J Cancer. 2010;103(3):401–410. doi:10.1038/sj.bjc.6605763
   PubMed Web of Science ®Google Scholar
• Bhatnagar S, Gazin C, Chamberlain L, et al. TRIM37 is a new histone H2A ubiquitin ligase and breast cancer oncoprotein. Nature. 2014;516(7529):116–120. doi:10.1038/nature13955
   PubMed Web of Science ®Google Scholar
• Gatza ML, Silva GO, Parker JS, Fan C, Perou CM. An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer. Nat Genet. 2014;46(10):1051–1059. doi:10.1038/ng.3073
   PubMed Web of Science ®Google Scholar
• Hartikainen JM, Tengstrom M, Kosma VM, Kinnula VL, Mannermaa A, Soini Y. Genetic polymorphisms and protein expression of NRF2 and Sulfiredoxin predict survival outcomes in breast cancer. Cancer Res. 2012;72(21):5537–5546. doi:10.1158/0008-5472.CAN-12-1474
   PubMed Web of Science ®Google Scholar
• Liu J, Li P, Wang R, et al. High expression of DLG3 is associated with decreased survival from breast cancer. Clin Exp Pharmacol Physiol. 2019;46(10):937–943. doi:10.1111/1440-1681.13132
   PubMed Web of Science ®Google Scholar
• Yousefnia S, Seyed Forootan F, Seyed Forootan S, Nasr Esfahani MH, Gure AO, Ghaedi K. Mechanistic pathways of malignancy in breast cancer stem cells. Front Oncol. 2020;10:452. doi:10.3389/fonc.2020.00452
   PubMed Web of Science ®Google Scholar
• Yousefnia S, Momenzadeh S, Seyed Forootan F, Ghaedi K, Nasr Esfahani MH. The influence of peroxisome proliferator-activated receptor gamma (PPARgamma) ligands on cancer cell tumorigenicity. Gene. 2018;649:14–22. doi:10.1016/j.gene.2018.01.018
   PubMed Web of Science ®Google Scholar
• Xiao S, Zhu H, Luo J, Wu Z, Xie M. miR4255p is associated with poor prognosis in patients with breast cancer and promotes cancer cell progression by targeting PTEN. Oncol Rep. 2019;42(6):2550–2560. doi:10.3892/or.2019.7371
   PubMed Web of Science ®Google Scholar
• Cao ZG, Li JJ, Yao L, et al. High expression of microRNA-454 is associated with poor prognosis in triple-negative breast cancer. Oncotarget. 2016;7(40):64900–64909. doi:10.18632/oncotarget.11764
   PubMedGoogle Scholar
• Sevinc ED, Egeli U, Cecener G, et al. Association of miR-1266 with recurrence/metastasis potential in estrogen receptor positive breast cancer patients. Asian Pac J Cancer Prev. 2015;16(1):291–297. doi:10.7314/APJCP.2015.16.1.291
   PubMedGoogle Scholar
• Giricz O, Reynolds PA, Ramnauth A, et al. Hsa-miR-375 is differentially expressed during breast lobular neoplasia and promotes loss of mammary acinar polarity. J Pathol. 2012;226(1):108–119. doi:10.1002/path.2978
   PubMed Web of Science ®Google Scholar
• Nagpal N, Ahmad HM, Molparia B, Kulshreshtha R. MicroRNA-191, an estrogen-responsive microRNA, functions as an oncogenic regulator in human breast cancer. Carcinogenesis. 2013;34(8):1889–1899. doi:10.1093/carcin/bgt107
   PubMed Web of Science ®Google Scholar
• Guan H, Dai Z, Ma Y, Wang Z, Liu X, Wang X. MicroRNA-101 inhibits cell proliferation and induces apoptosis by targeting EYA1 in breast cancer. Int J Mol Med. 2016;37(6):1643–1651. doi:10.3892/ijmm.2016.2557
   PubMed Web of Science ®Google Scholar
• Zhou W, Song F, Wu Q, et al. miR-217 inhibits triple-negative breast cancer cell growth, migration, and invasion through targeting KLF5. PLoS One. 2017;12(4):e0176395. doi:10.1371/journal.pone.0176395
   PubMed Web of Science ®Google Scholar
• Liu J, Zhou Y, Shi Z, et al. microRNA-497 modulates breast cancer cell proliferation, invasion, and survival by targeting SMAD7. DNA Cell Biol. 2016;35(9):521–529. doi:10.1089/dna.2016.3282
   PubMed Web of Science ®Google Scholar
• Yao L, Liu Y, Cao Z, et al. MicroRNA-493 is a prognostic factor in triple-negative breast cancer. Cancer Sci. 2018;109(7):2294–2301. doi:10.1111/cas.13644
   PubMed Web of Science ®Google Scholar
• Yu M, Zhang X, Li H, Zhang P, Dong W. MicroRNA-588 is downregulated and may have prognostic and functional roles in human breast cancer. Med Sci Monit. 2017;23:5690–5696. doi:10.12659/MSM.905126
   PubMed Web of Science ®Google Scholar
• Karmali PP, Brunquell C, Tram H, Ireland SK, Ruoslahti E, Biliran H. Metastasis of tumor cells is enhanced by downregulation of Bit1. PLoS One. 2011;6(8):e23840. doi:10.1371/journal.pone.0023840
   PubMed Web of Science ®Google Scholar
• Rizeq B, Sif S, Nasrallah GK, Ouhtit A. Novel role of BRCA1 interacting C-terminal helicase 1 (BRIP1) in breast tumour cell invasion. J Cell Mol Med. 2020;24(19):11477–11488. doi:10.1111/jcmm.15761
   PubMed Web of Science ®Google Scholar
• Zhao T, Du H, Ding X, Walls K, Yan C. Activation of mTOR pathway in myeloid-derived suppressor cells stimulates cancer cell proliferation and metastasis in lal(-/-) mice. Oncogene. 2015;34(15):1938–1948. doi:10.1038/onc.2014.143
   PubMed Web of Science ®Google Scholar
• Yan M, Jene N, Byrne D, et al. Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers. Breast Cancer Res. 2011;13(2):R47. doi:10.1186/bcr2869
   PubMed Web of Science ®Google Scholar
• Kalinowski DS, Richardson DR. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev. 2005;57(4):547–583. doi:10.1124/pr.57.4.2
   PubMed Web of Science ®Google Scholar
• Fonseca-Nunes A, Jakszyn P, Agudo A. Iron and cancer risk – a systematic review and meta-analysis of the epidemiological evidence. Cancer Epidemiol Biomarkers Prev. 2014;23(1):12–31. doi:10.1158/1055-9965.EPI-13-0733
   PubMed Web of Science ®Google Scholar
• Willis S, Villalobos VM, Gevaert O, et al. Single gene prognostic biomarkers in ovarian cancer: a meta-analysis. PLoS One. 2016;11(2):e0149183. doi:10.1371/journal.pone.0149183
   PubMed Web of Science ®Google Scholar
• Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007;7(10):763–777. doi:10.1038/nrc2222
   PubMed Web of Science ®Google Scholar
• Nusse R. Wnt signaling in disease and in development. Cell Res. 2005;15(1):28–32. doi:10.1038/sj.cr.7290260
   PubMed Web of Science ®Google Scholar
• Tzanakakis G, Giatagana EM, Kuskov A, et al. Proteoglycans in the pathogenesis of hormone-dependent cancers: mediators and effectors. Cancers. 2020;12(9):2401. doi:10.3390/cancers12092401
   PubMed Web of Science ®Google Scholar
• Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060–1072. doi:10.1016/j.cell.2012.03.042
   PubMed Web of Science ®Google Scholar
• Chen X, Kang R, Kroemer G, Tang D. Broadening horizons: the role of ferroptosis in cancer. Nat Rev Clin Oncol. 2021;18(5):280–296. doi:10.1038/s41571-020-00462-0
   PubMed Web of Science ®Google Scholar